Hematopoietic Support by Adipose-Derived Stromal Cells

骨髓移植需要大量的多能造血细胞 干细胞取得了成功的临床结果。因此，有一个迫在眉睫的 医学上需要在体外扩增干细胞并加速其 体内植入。这些步骤可能得到产生细胞因子的基质的支持 细胞。Artecel Science的科学家已经开发出专有技术来 从脂肪组织中分离培养人基质细胞，可用于 自体和异体移植。这篇SBIR调查的是假设 脂肪来源的基质细胞将(1)支持造血祖细胞 体外增殖和分化；(2)促进其体内植入。 目标1(阶段I)将证明人类脂肪来源的基质细胞将 支持多向和多向造血祖细胞的增殖 用流式细胞仪和甲基纤维素法进行短期和长期培养。这 这项工作为H阶段研究提供了基础，以确定：(目标3) 体外扩增的造血祖细胞在亚致死剂量照射后的再生 NOD/SCID小鼠；(目标4)脂肪来源的基质细胞加速 亚致死剂量照射的NOD/SCID小鼠的造血干细胞植入。 建议的商业应用： 这项SBIR将开发出适用于所有接受骨移植的患者的技术 骨髓移植。每年有20,000名接受这种疗法的患者 个人花费100,000美元。Artecel Sciences的技术有可能 大大减少了这些程序的临床和经济负担。

Bone marrow transplantation requires large numbers of pluripotent hematopoietic stem cells to achieve a successful clinical outcome. Therefore, there is a pressing medical need for methods to expand stem cells ex vivo and accelerate their engraftment in vivo. These steps may be supported by cytokine-producing stromal cells. The scientists at Artecel Sciences have developed proprietary techniques to isolate and culture human stromal cells from adipose tissue that can be used for autologous and allogeneic transplantation. This SBIR investigates the hypotheses that adipose derived stromal cells will (1) support hematopoietic progenitor cell proliferation and differentiation in vitro and (2) accelerate their engraftment in vivo. Aim 1 (Phase I) will demonstrate that human adipose derived stromal cells will support proliferation of multipotent and pluripotent hematopoietic progenitors in short and long term cultures using flow cytometric and methylcellulose assays. This work provides a foundation for Phase H studies to determine: (Aim 3) The ability of ex vivo expanded hematopoietic progenitors to repopulate sublethally irradiated NOD/SCID mice; (Aim 4) The ability of adipose derived stromal cells to accelerate hematopoietic stem cell engraftment in sublethally irradiated NOD/SCID mice. PROPOSED COMMERCIAL APPLICATION: This SBIR will develop technology with application to all patients receiving bone marrow transplantation. Each year, 20,000+ patients under this therapy at an individual cost of $100,000. Artecel Sciences technology has the potential to significantly reduce the clinical and financial burden of these procedures.